People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology, Other Health Care, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2014 |
| Camp4 Therapeutics Corp | — | Biotechnology | Series D+ | $179.6M | $2.2B | 2018 |
| Earli Inc. | — | Other Health Care | Series B | $40.0M | $756.4M | 2021 |
| Knome Inc | — | Other | Series A | $15.8M | $87.1M | 2010 |
Jorge Conde at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jorge Conde on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Amir Nashat | 2 | 14 |
| Stephane Bancel | 2 | 4 |
| Robert Nelsen | 1 | 22 |
| Srinivas Akkaraju | 1 | 10 |
| Michael Higgins | 1 | 9 |
| Andrew J. Schwab | 1 | 7 |
| Vicki Sato | 1 | 6 |
| Sundar Subramaniam | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Wolfgang Daum | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
| Justin Kao | 1 | 4 |
| Shaan Gandhi | 1 | 4 |
| Peter Wirth | 1 | 3 |
| Mark Alles | 1 | 3 |
| Timothy C. Tyson | 1 | 3 |
| Paula Ragan | 1 | 3 |
| Robert E. Nelsen | 1 | 3 |
| Alejandro Sanchez | 1 | 3 |
| James E. Bradner | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.